New research suggests that patients who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who end conventional lifestyle programs.
Research printed in a major health publication points out that while overweight individuals can lose a large proportion of their total mass while on the medication, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.
"People buying such treatments should be cognizant of the danger of quick weight regain when the medication ends," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery suggests a reversion to original weight within about 18 months.
Comparing Approaches
The analysis, which looked at dozens of trials involving thousands of participants, contrasted the effects of the injectable medications with conventional dieting.
The team point out that people who shed pounds through dieting typically experience a slower weight regain—around 0.1 kg a month—after stopping.
The Reason for the Fast Rebound
Experts suggest the way of the jabs explains the amplified weight return.
These medications mimic a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than normal may cause the body to produce less of its endogenous GLP-1, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this hormone supplement means appetite is unsuppressed, making excessive eating a significant risk."
A Chronic Disease?
The NHS recommend the jabs for individuals with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts say that, considering the likelihood of weight regain, the therapy is often ongoing.
This opinion is echoed by pharmaceutical companies, who state that the results "highlight the chronic nature of excess weight," akin to managing conditions like diabetes.
Patient Experiences
Individuals who have come off the jabs explain a intense return of cravings.
"I experienced a trigger activating and you're instantly starving," recalled an individual.
The struggle is exacerbated if patients have not established permanent dietary or behavioural modifications during therapy.
Widespread Interest
Recent estimates show that a significant number of people in the UK have tried these injections in the last 12 months, with interest remaining high.
- Use is higher among women compared to males.
- The middle-aged age group shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, clinicians stress that while the jabs are powerful agents for shedding pounds, they are not a permanent cure and long-term success likely depends on integrated lifestyle management.
